Education
About Us
Working with TipRanks
Follow Us
Astec Lifesciences Limited (IN:ASTEC)
:ASTEC
ASTEC Stock Chart & Stats
₹703.50
-₹43.60(-3.76%)
At close: 4:00 PM EST
₹703.50
-₹43.60(-3.76%)
Day’s Range― - ―
52-Week Range₹558.15 - ₹990.88
Previous CloseN/A
Volume22.45K
Average Volume (3M)412.49K
Market Cap
₹13.90B
Enterprise Value₹17.45B
Total Cash (Recent Filing)₹5.75M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)―
Beta1.34
Next Earnings
May 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.04
Shares Outstanding22,281,660
10 Day Avg. Volume47,730
30 Day Avg. Volume412,490
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)6.10
Price to Sales (P/S)3.76
P/FCF Ratio-47.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-21.45
Revenue Forecast (FY)₹5.29B
Bulls Say, Bears Say
Bulls Say
Vertical Integration And Product ScopeAstec's integrated manufacturing across actives, intermediates and formulations provides durable operational control and potential margin capture. Owning multiple production stages supports cost management, quality control and easier scaling versus pure-play suppliers over the next 2–6 months.
Diversified Revenue Channels (B2B And Formulations)Serving both B2B technical customers and formulated product markets spreads commercial risk and smooths demand swings. This multi-channel model supports steady plant utilization and revenue mix flexibility, improving resilience to single-market downturns over the medium term.
Positive Stockholders' Equity BufferMaintaining positive shareholder equity despite pressures offers a durable balance-sheet cushion. It preserves borrowing capacity and provides a capital buffer for operations or restructuring, giving the company more options to manage near-term stress without immediate insolvency risk.
Bears Say
Declining Revenue And Negative MarginsSustained revenue decline and negative net margins indicate the core business is under pricing or volume pressure. Over months this erodes reinvestment and product development capacity, making it harder to regain scale or improve profitability without structural changes to products or markets.
High And Rising LeverageIncreasing debt-to-equity raises interest and refinancing risk and constrains strategic flexibility. With elevated leverage, the company faces higher fixed costs and less room for capex or working-capital investment, increasing vulnerability to demand shocks or higher rates.
Negative Operating And Free Cash FlowConsistent negative operating and free cash flow erodes liquidity and forces reliance on external financing or asset sales. Over the medium term this limits the firm's ability to fund maintenance capex, repay debt, or invest in growth initiatives without diluting or levering further.
Astec Lifesciences Limited News
ASTEC FAQ
What was Astec Lifesciences Limited’s price range in the past 12 months?
Astec Lifesciences Limited lowest stock price was ₹558.15 and its highest was ₹990.88 in the past 12 months.
What is Astec Lifesciences Limited’s market cap?
Astec Lifesciences Limited’s market cap is ₹13.90B.
When is Astec Lifesciences Limited’s upcoming earnings report date?
Astec Lifesciences Limited’s upcoming earnings report date is May 06, 2026 which is in 64 days.
How were Astec Lifesciences Limited’s earnings last quarter?
Astec Lifesciences Limited released its earnings results on Jan 30, 2026. The company reported -₹7.04 earnings per share for the quarter, missing the consensus estimate of -₹6.3 by -₹0.74.
Is Astec Lifesciences Limited overvalued?
According to Wall Street analysts Astec Lifesciences Limited’s price is currently Overvalued.
Does Astec Lifesciences Limited pay dividends?
Astec Lifesciences Limited pays a Annually dividend of ₹1.5 which represents an annual dividend yield of N/A. See more information on Astec Lifesciences Limited dividends here
What is Astec Lifesciences Limited’s EPS estimate?
Astec Lifesciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Astec Lifesciences Limited have?
Astec Lifesciences Limited has 22,281,660 shares outstanding.
What happened to Astec Lifesciences Limited’s price movement after its last earnings report?
Astec Lifesciences Limited reported an EPS of -₹7.04 in its last earnings report, missing expectations of -₹6.3. Following the earnings report the stock price went down -0.243%.
Which hedge fund is a major shareholder of Astec Lifesciences Limited?
Currently, no hedge funds are holding shares in IN:ASTEC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Astec Lifesciences Limited
Astec Lifesciences Limited (ASTEC) is a leading manufacturer and supplier of agrochemicals and pharmaceutical intermediates based in India. The company operates primarily in the agrochemical sector, focusing on the production of herbicides, fungicides, insecticides, and other crop protection products. Additionally, ASTEC is involved in the development of pharmaceutical intermediates and specialty chemicals, catering to both domestic and international markets. Leveraging its strong research and development capabilities, the company aims to provide innovative solutions for sustainable agriculture and healthcare.
Technical Analysis
Heranba Industries Limited
―
IG Petrochemicals Ltd.
―
IOL Chemicals & Pharmaceuticals Ltd.
―
Punjab Chemicals & Crop Protection Ltd.
―
Uniphos Enterprises Limited
―